Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels

Suad Al-Abri, Kathryn H. Meier, Jennifer M. Colby, Craig G. Smollin, Neal L. Benowitz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Context. 4-Fluoroamphetamine (4-FA) is a para-substituted phenethylamine-type synthetic stimulant that has in recent years gained popularity through internet blogs and market share according to confiscated drug data. No serious toxicity has previously been reported. We report a case of a young man who developed severe toxicity and cardiogenic shock after using 4-FA, with laboratory confirmation. Case details. An 18-year-old man presented to the emergency department with vomiting, shortness of breath, chest tightness, and altered mental status about 5 h after using a new and unfamiliar street drug. Two days prior, he had received naltrexone intramuscular injection as part of an opioid addiction treatment program and was taking fluoxetine and trazodone. Five hours after presentation, he developed cardiogenic shock requiring intraaortic balloon pump, inotropic and ventilatory support. An echocardiogram showed left ventricular (LV) hypokinesia, sparing the apex and ejection fraction (EF) = 10%. Comprehensive toxicology serum testing revealed FA, naproxen, trazodone, and cotinine. The 4-FA urine level was 64,000 ng/ml and serum level was 118 ng/ml. With slow recovery, the patient was discharged after 2 weeks of hospitalization. Discussion. Although no previously reported 4-FA clinical poisoning cases have been published for comparison, by examining 4-FA pharmacology compared with other stimulant drugs, and given this patient's presentation and echocardiogram suggestive of reverse takotsubo cardiomyopathy we suspect the toxic mechanism was an acute cardiomyopathy caused by 4-FA catecholamine-induced myocarditis and/or small vessel myocardial ischemia. Conclusion. Recreational use of 4-FA may present with life threatening toxicity including cardiomyopathy, cardiogenic shock, and pulmonary edema.

Original languageEnglish
Pages (from-to)1292-1295
Number of pages4
JournalClinical Toxicology
Volume52
Issue number10
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Cardiogenic Shock
Urine
Serum
Trazodone
Toxicity
Cardiomyopathies
Blogging
Takotsubo Cardiomyopathy
Cotinine
Hypokinesia
Naltrexone
Naproxen
Blogs
Fluoxetine
Poisons
Balloons
Intramuscular Injections
Myocarditis
Street Drugs
Pulmonary Edema

Keywords

  • Cardiogenic shock
  • Designer drugs
  • Fluroamphetamine
  • Laboratory analysis
  • Reverse takotsubo cardiomyopathy

ASJC Scopus subject areas

  • Toxicology

Cite this

Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels. / Al-Abri, Suad; Meier, Kathryn H.; Colby, Jennifer M.; Smollin, Craig G.; Benowitz, Neal L.

In: Clinical Toxicology, Vol. 52, No. 10, 01.12.2014, p. 1292-1295.

Research output: Contribution to journalArticle

Al-Abri, Suad ; Meier, Kathryn H. ; Colby, Jennifer M. ; Smollin, Craig G. ; Benowitz, Neal L. / Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels. In: Clinical Toxicology. 2014 ; Vol. 52, No. 10. pp. 1292-1295.
@article{832fb340a720499684ce168097923f56,
title = "Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels",
abstract = "Context. 4-Fluoroamphetamine (4-FA) is a para-substituted phenethylamine-type synthetic stimulant that has in recent years gained popularity through internet blogs and market share according to confiscated drug data. No serious toxicity has previously been reported. We report a case of a young man who developed severe toxicity and cardiogenic shock after using 4-FA, with laboratory confirmation. Case details. An 18-year-old man presented to the emergency department with vomiting, shortness of breath, chest tightness, and altered mental status about 5 h after using a new and unfamiliar street drug. Two days prior, he had received naltrexone intramuscular injection as part of an opioid addiction treatment program and was taking fluoxetine and trazodone. Five hours after presentation, he developed cardiogenic shock requiring intraaortic balloon pump, inotropic and ventilatory support. An echocardiogram showed left ventricular (LV) hypokinesia, sparing the apex and ejection fraction (EF) = 10{\%}. Comprehensive toxicology serum testing revealed FA, naproxen, trazodone, and cotinine. The 4-FA urine level was 64,000 ng/ml and serum level was 118 ng/ml. With slow recovery, the patient was discharged after 2 weeks of hospitalization. Discussion. Although no previously reported 4-FA clinical poisoning cases have been published for comparison, by examining 4-FA pharmacology compared with other stimulant drugs, and given this patient's presentation and echocardiogram suggestive of reverse takotsubo cardiomyopathy we suspect the toxic mechanism was an acute cardiomyopathy caused by 4-FA catecholamine-induced myocarditis and/or small vessel myocardial ischemia. Conclusion. Recreational use of 4-FA may present with life threatening toxicity including cardiomyopathy, cardiogenic shock, and pulmonary edema.",
keywords = "Cardiogenic shock, Designer drugs, Fluroamphetamine, Laboratory analysis, Reverse takotsubo cardiomyopathy",
author = "Suad Al-Abri and Meier, {Kathryn H.} and Colby, {Jennifer M.} and Smollin, {Craig G.} and Benowitz, {Neal L.}",
year = "2014",
month = "12",
day = "1",
doi = "10.3109/15563650.2014.974262",
language = "English",
volume = "52",
pages = "1292--1295",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels

AU - Al-Abri, Suad

AU - Meier, Kathryn H.

AU - Colby, Jennifer M.

AU - Smollin, Craig G.

AU - Benowitz, Neal L.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Context. 4-Fluoroamphetamine (4-FA) is a para-substituted phenethylamine-type synthetic stimulant that has in recent years gained popularity through internet blogs and market share according to confiscated drug data. No serious toxicity has previously been reported. We report a case of a young man who developed severe toxicity and cardiogenic shock after using 4-FA, with laboratory confirmation. Case details. An 18-year-old man presented to the emergency department with vomiting, shortness of breath, chest tightness, and altered mental status about 5 h after using a new and unfamiliar street drug. Two days prior, he had received naltrexone intramuscular injection as part of an opioid addiction treatment program and was taking fluoxetine and trazodone. Five hours after presentation, he developed cardiogenic shock requiring intraaortic balloon pump, inotropic and ventilatory support. An echocardiogram showed left ventricular (LV) hypokinesia, sparing the apex and ejection fraction (EF) = 10%. Comprehensive toxicology serum testing revealed FA, naproxen, trazodone, and cotinine. The 4-FA urine level was 64,000 ng/ml and serum level was 118 ng/ml. With slow recovery, the patient was discharged after 2 weeks of hospitalization. Discussion. Although no previously reported 4-FA clinical poisoning cases have been published for comparison, by examining 4-FA pharmacology compared with other stimulant drugs, and given this patient's presentation and echocardiogram suggestive of reverse takotsubo cardiomyopathy we suspect the toxic mechanism was an acute cardiomyopathy caused by 4-FA catecholamine-induced myocarditis and/or small vessel myocardial ischemia. Conclusion. Recreational use of 4-FA may present with life threatening toxicity including cardiomyopathy, cardiogenic shock, and pulmonary edema.

AB - Context. 4-Fluoroamphetamine (4-FA) is a para-substituted phenethylamine-type synthetic stimulant that has in recent years gained popularity through internet blogs and market share according to confiscated drug data. No serious toxicity has previously been reported. We report a case of a young man who developed severe toxicity and cardiogenic shock after using 4-FA, with laboratory confirmation. Case details. An 18-year-old man presented to the emergency department with vomiting, shortness of breath, chest tightness, and altered mental status about 5 h after using a new and unfamiliar street drug. Two days prior, he had received naltrexone intramuscular injection as part of an opioid addiction treatment program and was taking fluoxetine and trazodone. Five hours after presentation, he developed cardiogenic shock requiring intraaortic balloon pump, inotropic and ventilatory support. An echocardiogram showed left ventricular (LV) hypokinesia, sparing the apex and ejection fraction (EF) = 10%. Comprehensive toxicology serum testing revealed FA, naproxen, trazodone, and cotinine. The 4-FA urine level was 64,000 ng/ml and serum level was 118 ng/ml. With slow recovery, the patient was discharged after 2 weeks of hospitalization. Discussion. Although no previously reported 4-FA clinical poisoning cases have been published for comparison, by examining 4-FA pharmacology compared with other stimulant drugs, and given this patient's presentation and echocardiogram suggestive of reverse takotsubo cardiomyopathy we suspect the toxic mechanism was an acute cardiomyopathy caused by 4-FA catecholamine-induced myocarditis and/or small vessel myocardial ischemia. Conclusion. Recreational use of 4-FA may present with life threatening toxicity including cardiomyopathy, cardiogenic shock, and pulmonary edema.

KW - Cardiogenic shock

KW - Designer drugs

KW - Fluroamphetamine

KW - Laboratory analysis

KW - Reverse takotsubo cardiomyopathy

UR - http://www.scopus.com/inward/record.url?scp=84920046073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920046073&partnerID=8YFLogxK

U2 - 10.3109/15563650.2014.974262

DO - 10.3109/15563650.2014.974262

M3 - Article

VL - 52

SP - 1292

EP - 1295

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

IS - 10

ER -